ClinicalTrials.gg
CompletedNCT00047476Updated Jun 24, 2005

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

A Phase 2 interventional study of dexmethylphenidate(d-mph) in Fatigue and Neoplasms, sponsored by Celgene Corporation. Completed at 21 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 704 studies in Fatigue with a site in United States — 91 open to participants now, 113 under way, 10 of them phase 3. Fatigue · United States.

Enrollment
116th of 610
160 · median 47
Started
2002
with 12 others
Phase 2
76 of 704
6 open now
Registered
15th of 704
by date

Among the 704 studies in Fatigue with a site in United States, this one is the 116th largest by enrollment of the 610 interventional ones that give a count, is one of 13 that started in 2002, is one of 76 in phase 2, and was the 15th registered.

Fatigue

2,232 studies on the registry are indexed under Fatigue; 427 are open to participants now.

Browse Fatigue studies →

Open to participants now

91 of the 704 studies in Fatigue with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 239 Fatigue studies recruiting now, 111 (46%) set no upper age limit and 98 (41%) stop at 75 or younger; 23 take children under 18; 73 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 704 studies in Fatigue with a site in United States, or all of them as a file.
02

Study summary

To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.

03

Conditions studied

  • Fatigue
  • Neoplasms

Keywords

  • neurobehavioral function
  • chemobrain
  • chemo brain
  • fatigue
  • memory loss
  • exhausted
  • trouble concentrating
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Diagnosis of cancer, excluding primary or brain tumors.
  • Treated with a minimum of four cycles of a cytotoxic chemotherapy, the last chemotherapy treatment must have been completed at least 2 months prior to study entry.
  • Physical/neurological examination consistent with the absence of a focal neurological deficit
  • Women of (WCBP) must have a negative serum or urine pregnancy test. In addition, sexually active WCBP must agree to use adequate methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner).
  • Subjects must be able to adhere to the protocol requirements.
  • Subjects must understand and voluntarily sign an document.
  • Subjects must be a native English speaker or fluent in English, and have at least an eighth grade education.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
160 participants

Interventions

06

Study locations

21 sites
  • Cooper Green Hospital, Jefferson Clinic
    Birmingham, Alabama 35233, United States
  • University of Alabama Palliative Care Institute
    Birmingham, Alabama 35294-0023, United States
  • Peak Performance Wellness
    Flagstaff, Arizona 86004, United States
  • Arizona Clinical Research Center
    Tucson, Arizona 85712, United States
  • Alta Bates Comprehensive Cancer Center
    Berkeley, California 94704, United States
  • California Cancer Care Inc
    Greenbrae, California 94904-2007, United States
  • Clinical Trials and Research Associates
    Montebello, California 90640, United States
  • Comprehensive Cancer Centers of the Desert
    Palm Springs, California 92262, United States
  • Comprehensive Cancer Center
    Boca Raton, Florida 33428, United States
  • Osler Clinical Research/Osler Medical Inc
    Melbourne, Florida 32901, United States
  • University of Miami, Sylvester Cancer Research Center
    Miami, Florida 33139, United States
  • Cancer Research Network Inc
    Plantation, Florida 33324, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33162, United States
  • Piedmont Hospital
    Atlanta, Georgia 30309, United States
  • Markey Cancer Center
    Lexington, Kentucky 40536, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Beth Israel Cancer Center
    New York, New York 10003, United States
  • Gynecologic Oncology Associates and Development LLC
    Greenville, South Carolina 29604, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109-1023, United States
  • Northwest Medical Specialists, PLLC
    Tacoma, Washington 98405, United States
  • UW Comprehensive Cancer Center
    Madison, Wisconsin 53792-6164, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2002
First posted
Oct 9, 2002
Start
Jun 2002
Completion
Mar 2004
Last update
Jun 24, 2005
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00047476
First posted
Oct 9, 2002
Start date
Jun 2002
Completion
Mar 2004
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2004. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion